Key result
Pharmacological inhibition of the transcription factor FOXO1 prevented statin-induced myopathy in human iPS cell-derived myocytes.
Why the study?
Does pharmacological inhibition of FOXO1 prevent statin-induced myopathy in human iPS cell-derived myocytes?
Does pharmacological inhibition of FOXO1 prevent statin-induced myopathy in human iPS cell-derived myocytes?
FOXO1 inhibition prevents statin-induced myopathy in a human iPSC model, identifying a novel target for preventing statin myotoxicity.
Answers are grounded in this paper and cite their sources.
FOXO1 inhibition may mitigate statin myopathy; hypothesis-generating in iPSC models and should not yet change practice.
This work established a human induced pluripotent stem (iPS) cell-based model for statin-induced myopathy (SIM) and demonstrated that blocking the mevalonate pathway disrupts the balance between protein synthesis and degradation, leading to myopathy. Furthermore, the present study showed that pharmacological inhibition of the transcription factor FOXO1 prevents SIM in human iPS cell-derived myocytes, suggesting that FOXO1 is a key mediator of SIM and a potential target for its prevention.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied Statin-induced myopathy. Pharmacological inhibition of FOXO1 was evaluated on Prevention of statin-induced myopathy in human iPS cell-derived myocytes. Pharmacological inhibition of the transcription factor FOXO1 prevented statin-induced myopathy in human iPS cell-derived myocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: